What it is
BPC-157 is a peptide, which means a short chain of amino acids (the building blocks of proteins). It has 15 amino acids. The BPC-157 used in studies and sold today is made in a laboratory by chemical synthesis. It is not extracted from the body.
More on what it is and where it came from
It has been studied since the early 1990s, mostly in rats and mice. In those animal studies it has been tested on cut tendons and ligaments, crushed muscle, and several kinds of gut damage. A drug company also tested it in people in the early 2000s as a possible treatment for ulcerative colitis (a long-term inflammatory disease of the large bowel), under the code names PL 14736 and PLD-116.
No medicine containing BPC-157 has been approved in any country, according to a 2026 review by the U.S. Food and Drug Administration (FDA). The FDA also noted that different chemical forms (the plain peptide, called the free base, and a salt form called the acetate) are sold under the same name, which makes it harder to know exactly what a given product contains.
BPC-157 was first described in 1993 by Predrag Sikiric and colleagues at the University of Zagreb medical school in Croatia. They reported isolating a larger protein from stomach (gastric) juice, which they named BPC, with a size of about 40,000 daltons. BPC-157 is a 15-amino-acid piece of that protein which the group said was 'thought to be essential for its activity'. So 'derived from gastric juice' means the sequence was reported to come from a stomach-juice protein; the BPC-157 used in research is a synthetic copy of that piece. Later papers from the same group say the pharmaceutical company Pliva took it into clinical trials for inflammatory bowel disease as PL 14736 / PLD-116. A 2015 safety trial was registered by a company called PharmaCotherapia under the name Bepecin.
How it is thought to work
Nobody has shown exactly how BPC-157 works. In its 2026 review the FDA wrote that the molecule's targets in the body 'have not been identified' and that its mechanisms 'remain poorly understood'. The agency also noted that the rat studies did not show a clear link between the amount given and the size of the effect, which makes the results harder to interpret.
More on how it works
Researchers have proposed several ideas, all from animal or cell experiments. In rat tendon cells grown in a dish, a Taiwanese group found that BPC-157 helped the cells survive stress and move, and switched on a signalling route inside cells called FAK-paxillin. The same group reported that it increased the growth of new blood vessels (angiogenesis) in a chick-egg membrane test and in rats with reduced blood flow to a leg, together with higher levels of a blood-vessel growth receptor called VEGFR2. The Zagreb group has linked its effects to the body's nitric oxide system, which helps control blood vessels.
In rats and dogs the peptide was cleared from the blood quickly: one study measured a half-life of under 30 minutes. How it behaves in the human body after being swallowed or injected under the skin has not been measured in any published study the FDA could find.
What is established in people
Very little is established in people. The FDA counted five small human studies in 2026: an enema study in 32 healthy men, a two-week enema trial in 53 people with ulcerative colitis that did not show a clear benefit and was reported only as a conference abstract, and three uncontrolled reports from private clinics in Florida covering 17 people with knee pain, 12 women with a bladder pain condition, and 2 people given an infusion. None tested the tendon, ligament or muscle uses that BPC-157 is best known for. A placebo-controlled trial in 120 people with hamstring strains was registered in China in 2026 and a 30-person trial after shoulder surgery was registered in the United States for 2027, but neither has reported results; a 40-person open-label trial of a BPC-157 gummy finished in 2025 with no results posted.
What the studies found
14 studies, human trials first. Each links to the paper or registry record.
- Human trial2026
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI (NCT07437547)
The trial was listed as recruiting, with a start date of 2 February 2026.
Full finding, who was studied, and limits
Who: A planned 120 people with a scan-confirmed hamstring strain at a hospital in Shenzhen, China, split at random between BPC-157 and placebo, with patients and staff unaware of who gets which. Sponsor: Hudson Biotech.
The trial was listed as recruiting, with a start date of 2 February 2026. No results exist yet. The registry estimates the main results in February 2027.
Read with care: A registration is a plan, not evidence. If it finishes and is published, it would be the first properly controlled human trial of BPC-157 for a muscle injury.
- Human trial2025
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
Blood tests for the heart, liver, kidneys, thyroid and blood sugar did not change in a measurable way, and neither person reported side effects.
Full finding, who was studied, and limits
Who: Two adults (a 58-year-old man and a 68-year-old woman) at a private clinic in Florida, given an infusion into a vein on two days in a row. Both had received intravenous BPC-157 before the study.
Blood tests for the heart, liver, kidneys, thyroid and blood sugar did not change in a measurable way, and neither person reported side effects.
Read with care: Two people cannot show that something is safe. There was no comparison group, follow-up lasted three days, and both participants had already tolerated the peptide before, which makes a problem less likely to show up. It did not measure blood levels of the peptide.
Alternative Therapies in Health and Medicine · pubmed.ncbi.nlm.nih.gov
- Human trial2021
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.
By the paper's own summary, 11 of the 12 people who had BPC-157 alone said their knee pain improved significantly, and 14 of 16 overall reported relief.
Full finding, who was studied, and limits
Who: A look back at the records of 17 patients with knee pain at one private clinic in Florida who had been given an injection into the knee joint. 16 were reached by phone, 6 to 12 months later. 12 had BPC-157 alone and 4 had it with another peptide.
By the paper's own summary, 11 of the 12 people who had BPC-157 alone said their knee pain improved significantly, and 14 of 16 overall reported relief.
Read with care: No comparison group, so there is no way to separate the injection's effect from placebo or natural recovery. Pain was rated from memory over the phone. No scans and no standard measuring tools were used. The cause of the knee pain varied. A 2025 systematic review reports the same study as 7 of 12 patients having relief for more than six months, so the headline figure depends on how 'improved' is counted.
Alternative Therapies in Health and Medicine · pubmed.ncbi.nlm.nih.gov
- Human trial2015
PCO-02 - Safety and Pharmacokinetics Trial (NCT02637284)
No results have been posted.
Full finding, who was studied, and limits
Who: A planned phase 1 trial in 42 healthy volunteers in Tijuana, Mexico, comparing BPC-157 tablets (called Bepecin or PCO-02) with placebo. Sponsor: PharmaCotherapia d.o.o.
No results have been posted. The registry lists the status as 'Unknown' and the record was last updated in December 2015. The FDA searched for a published paper from this trial in 2025 and could not find one.
Read with care: This was the only registered trial designed to measure how the peptide behaves in the human body after being swallowed. Its results were never made public, so that question is still open.
- Human trial2005
A Multicenter, Randomized, Double Blind, Placebo-Controlled Phase II Study of PL 14736 Enema in the Treatment of Mild-to-Moderate Ulcerative Colitis
This is the largest human trial found.
Full finding, who was studied, and limits
Who: 53 adults with mild to moderate ulcerative colitis, split evenly at random between a BPC-157 enema and a dummy enema, once a day for two weeks. 46 finished.
This is the largest human trial found. The disease score fell by 3.2 points on average with BPC-157 and by 1.6 points with placebo. The estimated gap between the groups was 1.6 points, but the range of uncertainty ran from 4.84 points in favour to 1.62 points against, so the trial did not show a clear difference. Three people on BPC-157 and two on placebo stopped because of side effects, mainly their colitis getting worse.
Read with care: The FDA could find this trial only as a short meeting abstract; it found no full published paper. The scoring method, entry rules and statistics were not fully described. Two weeks is very short for a long-term disease. The FDA concluded the data were 'inadequate to support the efficacy and safety' of the enema for ulcerative colitis.
- Human trial2003
Safety, Tolerability and Pharmacokinetics of PL 14736, a Novel Agent for Treatment of Ulcerative Colitis, in Healthy Male Volunteers
The authors reported no significant side effects that could be blamed on the peptide.
Full finding, who was studied, and limits
Who: 32 healthy men in a placebo-controlled phase 1 study; 24 received BPC-157 as an enema and 8 received placebo. Each had one dose, then a week off, then seven daily doses.
The authors reported no significant side effects that could be blamed on the peptide. The most common complaints were headache and wind, with no obvious difference from placebo. BPC-157 was not detected in most blood samples, which suggests little of it reached the bloodstream from an enema.
Read with care: Reported only as meeting abstracts with, in the FDA's words, no further details. Small, short, men only, and a route (enema) that says little about swallowing or injecting.
- Review2026
Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 (Free Base) and BPC-157 Acetate) for Inclusion on the 503A Bulk Drug Substances List
The FDA found five small human studies in total.
Full finding, who was studied, and limits
Who: FDA scientists reviewed the published chemistry, animal and human data on BPC-157, and the FDA's own side-effect report databases, for use in ulcerative colitis.
The FDA found five small human studies in total. It concluded there was 'a lack of evidence to support the effectiveness' of BPC-157 for ulcerative colitis and 'insufficient clinical safety information to characterize the safety profile'. It found no human studies at all of BPC-157 taken by mouth, injected under the skin, sprayed in the nose or applied through the skin for that condition, and no cancer-risk studies in animals. It proposed not adding BPC-157 to the list of substances pharmacies may compound.
Read with care: The FDA only assessed ulcerative colitis in detail, because the applications gave too little information on the other proposed uses. This is a staff review written for an advisory meeting, not a final agency decision; the advisory committee later voted the other way.
FDA briefing document for the Pharmacy Compounding Advisory Committee, dated 11 May 2026 · fda.gov
- Review2025
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
35 of the 36 studies were in animals or cells and one was in people (the knee-pain record review above).
Full finding, who was studied, and limits
Who: A structured search of three medical databases up to June 2024 by surgeons at Case Western Reserve University. 544 papers found; 36 included.
35 of the 36 studies were in animals or cells and one was in people (the knee-pain record review above). The animal studies reported better healing of muscle, tendon, ligament and bone. The authors wrote: 'No clinical safety data were found.' They called the evidence promising but preliminary and advised caution.
Read with care: A review can only be as strong as the studies it gathers, and here nearly all were animal studies. It covered sports injuries only and stopped in mid-2024.
- Review1993
A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC.
The authors reported that a new stomach-juice protein of about 40,000 daltons, named BPC, had recently been isolated, and that a 15-amino-acid fragment, BPC 157, had been characterised and tested.
Full finding, who was studied, and limits
Who: An overview paper by the discovering group at the University of Zagreb. It summarised their own early animal experiments; it did not report a single defined study group.
The authors reported that a new stomach-juice protein of about 40,000 daltons, named BPC, had recently been isolated, and that a 15-amino-acid fragment, BPC 157, had been characterised and tested. They said it protected many organs in several animal species and that no toxicity was seen.
Read with care: This is the group's own summary, not an independent test. It gives no group sizes. The full parent protein is not described in detail here, and I found no entry for it in the UniProt protein database.
- Animal study2010
Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat.
Rats given BPC 157 by injection into the abdomen, in drinking water, or as a cream on the injury showed better function, stronger ligaments in mechanical tests, and better tissue appearance than untreated rats.
Full finding, who was studied, and limits
Who: Rats whose medial collateral ligament (a ligament on the inner side of the knee) was cut surgically, followed for up to 90 days. The abstract does not give the number of animals.
Rats given BPC 157 by injection into the abdomen, in drinking water, or as a cream on the injury showed better function, stronger ligaments in mechanical tests, and better tissue appearance than untreated rats.
Read with care: Rats, not people. Done by the Zagreb group. Animal numbers are not in the abstract. No independent group has published a repeat of this ligament experiment that I found.
- Animal study2008
Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat.
Treated rats had less bruising and swelling, no stiffening of the leg, better muscle tissue under the microscope, better function, and blood enzyme levels that pointed to less muscle damage.
Full finding, who was studied, and limits
Who: Rats given a standard crush injury to the calf muscle, treated by injection into the abdomen or with a cream on the injury, for up to 14 days. The abstract does not give the number of animals.
Treated rats had less bruising and swelling, no stiffening of the leg, better muscle tissue under the microscope, better function, and blood enzyme levels that pointed to less muscle damage.
Read with care: Rats, not people. Done by the Zagreb group. Short follow-up. Animal numbers are not in the abstract.
- Animal study2008
Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system.
BPC 157 given in drinking water or by injection sped up healing of both the colon and skin openings, and the fistulas closed.
Full finding, who was studied, and limits
Who: Rats with a surgically made fistula (an abnormal channel) between the colon and the skin, followed for up to 28 days. Compared with untreated rats and with two standard bowel drugs.
BPC 157 given in drinking water or by injection sped up healing of both the colon and skin openings, and the fistulas closed. The FDA's summary of this paper says that from day 3 the fistulas were about 40% smaller in treated rats, and that by day 28 they appeared closed in treated rats while they had shrunk by less than 25% in untreated rats.
Read with care: Rats, not people. Done by the Zagreb group. The FDA noted the authors gave no microscope data on the healed tissue, that the two amounts tested worked equally well so no dose-response could be shown, and that treatment started 30 minutes after surgery, so it is unknown whether later treatment would work.
Journal of Pharmacological Sciences · pubmed.ncbi.nlm.nih.gov
- Animal study2003
Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth.
Over 14 days, treated rats had stronger tendons in mechanical tests, better movement scores, and better-looking tissue under the microscope than untreated rats.
Full finding, who was studied, and limits
Who: Rats whose right Achilles tendon was cut through, compared with rats given salt water. Also tendon cells grown in a dish. The abstract does not give the number of animals.
Over 14 days, treated rats had stronger tendons in mechanical tests, better movement scores, and better-looking tissue under the microscope than untreated rats. The authors reported the tendon regained full integrity. In the dish, BPC 157 on its own did not change cell growth, but it cancelled out the effect of a chemical that slows growth.
Read with care: Rats, not people. A clean surgical cut in a healthy young animal is not the same as a human tendon injury. Done by the Zagreb group that discovered the peptide. Animal numbers are not in the abstract.
- Cell study2011
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.
BPC 157 sped up the outgrowth of cells from tendon pieces, helped cells survive chemical stress, and increased cell movement and spreading.
Full finding, who was studied, and limits
Who: Pieces of rat Achilles tendon and tendon cells (fibroblasts) grown in a dish. Done at Chang Gung University in Taiwan, a group separate from the discoverers.
BPC 157 sped up the outgrowth of cells from tendon pieces, helped cells survive chemical stress, and increased cell movement and spreading. It did not directly make the cells multiply faster. The authors linked the effects to a cell signalling route called FAK-paxillin.
Read with care: Cells in a dish, not a living animal or person. It shows a possible mechanism, not a treatment result.
Safety findings
- Across the five small human studies it found, the FDA wrote that 'no serious adverse events appear to have been reported', but added that the studies were short, small, used exploratory amounts, and gave limited information on how safety was checked. Source: fda.gov
- In the phase 1 enema study in healthy men, the most common complaints were headache and wind, with no obvious difference from placebo. In the ulcerative colitis trial, three people on BPC-157 and two on placebo stopped because of side effects, mainly their colitis getting worse. These details come from the FDA's summary of conference abstracts. Source: fda.gov
- The FDA's side-effect database held three reports involving injected BPC-157 up to 4 December 2025: redness and swelling at the injection site for nine days; shortness of breath that led to an emergency room visit; and widespread skin darkening and darkening of the gums in a woman using a product that combined BPC-157 with another peptide and was labelled for research purposes only. The darkening came back when she used the product again. In every case another product or missing detail meant the FDA could not say BPC-157 was the cause. Source: fda.gov
- There are no long-term human safety data. The longest human exposure the FDA found was two weeks. The FDA found no published measurements of how the peptide is absorbed or cleared in people after being swallowed or injected under the skin. Source: fda.gov
4 more safety findings
- Animal safety testing: a Chinese group reported that BPC-157 was well tolerated in mice, rats, rabbits and dogs in tests lasting up to 28 days, with no genetic damage and no harm to unborn rats. Reading the same paper, the FDA pointed to changes in blood-clotting time in rats and dogs and liver-related blood changes in female rats, said the tissue data were not shown, and noted that no longer studies and no cancer studies in animals exist. Source: pubmed.ncbi.nlm.nih.gov
- Theoretical concern, immune reaction: the FDA said injected or nasal BPC-157 'may pose a significant risk for immunogenicity' (the body making an immune response to the peptide), made more likely by clumping of the peptide and by impurities. It also said no study has formally tested this for BPC-157. This is a risk the FDA could not rule out, not an effect seen in patients. Source: fda.gov
- Theoretical concern, blood vessels and tumours: because BPC-157 increased blood-vessel growth and a blood-vessel growth receptor (VEGFR2) in animal and cell studies, and tumours need new blood vessels to grow, a 2025 review by Polish pharmacy researchers warned it might be unwise where an undetected cancer could be present. They also noted that no study has directly tested this. The Zagreb group replied in the same journal that the concern is mistaken and cited their own cell and mouse work. There are no human data either way, and no animal cancer studies. Source: pmc.ncbi.nlm.nih.gov
- Product quality is a separate safety issue. The FDA said the safety of a BPC-157 product can be affected by its formulation, concentration and storage, which can produce impurities or clumps of peptide, and that it has seen different salts and even different molecules sold under the same name. Source: fda.gov
Rules and status
Not an FDA-approved drug. As of 18 November 2026 it is not on the FDA's list of substances pharmacies may compound from (the section 503A bulks list). Since 30 October 2026 it has been named in a draft enforcement-discretion policy from the U.S. Department of Health and Human Services (HHS), which is not an approval and does not put it on that list.
The full history, with dates
Approval: no product containing BPC-157 is FDA-approved, and the FDA found none approved in any other country. Category 2 (2023 to 2026): in September 2023 the FDA placed BPC-157 in 'Category 2' of its interim compounding policy, the group of nominated substances that 'may present significant safety risks'. The FDA's stated reasons were that compounded BPC-157 'may pose risk for immunogenicity for certain routes of administration', may have complexities with peptide-related impurities and with characterising the ingredient, and that the FDA had 'no, or only limited, safety-related information' and so could not know whether it would cause harm. What was announced in early 2026: news outlets reported that the HHS Secretary said on a podcast in late February 2026 that about 14 peptides would be moved back to Category 1. I found no document of that date on FDA.gov or in the Federal Register. What formally happened: BPC-157 then left Category 2, not because it was moved to Category 1 but because the companies that had nominated it withdrew their nominations. The FDA page that shows it in the "nominated but withdrawn" table is dated 22 April 2026; the page does not give the day of the change. The FDA's category list dated 14 May 2026 shows BPC-157 in no category. HHS later wrote that neither the placement in Category 2 nor the removal changed its legal status under section 503A. On 16 April 2026 the FDA published a Federal Register notice calling an advisory committee meeting for 23 and 24 July 2026. FDA staff, in a briefing dated 11 May 2026, proposed NOT adding BPC-157 to the 503A list. HHS states that the committee voted in favour of adding it. A committee vote is advice only. On 30 October 2026 HHS published a notice (91 FR 68526) announcing a draft 'Enforcement Discretion Policy' for six peptides. Appendix A of the policy (on hhs.gov, read from an Internet Archive capture of 15 November 2026) names exactly six: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. It says HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians who compound BPC-157 acetate, in the dosage forms the policy names, if ten conditions are met, including a patient-specific prescription, a single active ingredient, a certificate of analysis from an FDA-registered manufacturer, and reporting of serious side effects. HHS gives three reasons for including BPC-157 in Appendix B: historical use and multiple human studies are now documented; a lot-specific certificate from an FDA-registered facility now reports the identity, impurity, endotoxin, microbial and residual-solvent results the FDA had found lacking; and the policy's conditions (lot-level testing, single-ingredient products and MedWatch reporting) address the risks. The notice calls the policy a draft, says it 'does not establish any rights for any person and is not binding on HHS or the public', gave two weeks for public comment (closed mid-November 2026), and states no separate effective date. It applies until a final rule decides whether each peptide goes on the 503A list. As of 18 November 2026 a search of the Federal Register found no proposed or final rule adding BPC-157 to that list. The policy does not cover products sold as 'research use only' and is not a finding that BPC-157 is safe or effective.
Source: govinfo.gov (source dated 2026-10-30)
In sport: Prohibited at all times, in and out of competition, under class S0 (Non-approved substances), where it is named. The 2026 List (in force from 1 January 2026) says S0 'covers many different substances including but not limited to BPC-157', and states that all substances in S0 are Specified Substances. The 2027 List (published 21 September 2026, in force from 1 January 2027) keeps the same words and adds 'peptides' to the examples of non-approved substances. WADA first named it in the 2022 List. WADA
Claims and what the evidence supports
| What people say | What the evidence supports |
|---|---|
| BPC-157 heals tendon, ligament and muscle injuries. | In rats, yes: several studies reported faster healing after tendons, ligaments or muscles were cut or crushed. In people this has not been tested in a controlled trial. A 2025 systematic review found 35 animal or cell studies and one human study, which was a phone survey of knee-pain patients with no comparison group. The first placebo-controlled trial for a muscle injury was registered in 2026 and has no results yet. Source: pmc.ncbi.nlm.nih.gov |
| It comes from your own stomach juice, so it is natural and safe. | The sequence was reported in 1993 as a fragment of a protein found in stomach juice. The BPC-157 studied and sold is made synthetically. Being related to a body protein does not establish safety: the FDA concluded in 2026 that there is 'insufficient clinical safety information to characterize the safety profile'. Source: pubmed.ncbi.nlm.nih.gov |
| Human trials have shown it is safe. | The FDA found five human studies. All were small and short, the longest lasting two weeks, and most gave little detail on how side effects were checked. No serious side effects were reported in them, but studies of that size cannot detect uncommon or delayed problems. One planned safety trial in 42 volunteers never published results. Source: fda.gov |
| It heals the gut and treats ulcerative colitis. | Rat studies reported protection against several kinds of gut injury. The one human trial, in 53 people for two weeks, did not show a clear difference from placebo and was only ever reported as a conference abstract. The FDA concluded the data 'do not support the use of BPC-157 for the treatment of UC'. U.S. gastroenterology guidelines do not mention it. Source: fda.gov |
| It works throughout the body when swallowed. | Unknown in people. The FDA found no published human data on how BPC-157 is absorbed after being taken by mouth. In rats and dogs, injected BPC-157 was cleared from the blood in under 30 minutes. The 2026 HHS policy itself says that getting enough of any peptide into the body by mouth 'is inherently difficult and complex'. Source: pubmed.ncbi.nlm.nih.gov |
| The FDA approved BPC-157 (or made it legal again) in 2026. | It is not approved. FDA staff recommended against adding it to the pharmacy compounding list. What exists is a draft HHS policy, published 30 October 2026, saying HHS does not intend to take enforcement action against licensed pharmacies and physicians who compound it under ten conditions while a rule is worked out. The policy states it creates no rights and is not binding. Source: govinfo.gov |
| It is fine for competitive athletes because it is not a steroid. | It is banned in sport at all times. The World Anti-Doping Agency names BPC-157 in its Prohibited List under S0, Non-approved substances. Source: wada-ama.org |
What a genuine lab report should show
- Identity by mass spectrometry: the measured mass should match the expected molecular weight of about 1419.5 g/mol for the free base (formula C62H98N16O22). The report should also confirm the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
- The report should state which chemical form was tested: the free base (CAS 137525-51-0) or the acetate salt (the FDA lists CAS 216441-37-1). The FDA found documents where the name, CAS number and certificate did not match each other, and has seen different molecules sold under the name BPC-157.
- Purity by HPLC (a method that separates a sample into its components), with peptide-related impurities reported. The FDA specifically flagged peptide-related impurities and clumped peptide (aggregates) as concerns for BPC-157.
- Microbial quality: bacterial endotoxin and bioburden or sterility results. The FDA named these as critical for any injectable form, and the 2026 HHS policy lists endotoxins, heavy metals, microbial contamination and impurities as things a certificate of analysis should cover.
- A lot-specific certificate: the results should be tied to the batch number on the vial, name the testing laboratory, and be dated. The 2026 HHS policy expects the certificate to show the original manufacturer and its physical location.
- Content (how much peptide is actually in the vial), since purity and quantity are different measurements.
What is not known
- Does BPC-157 do anything useful in people? No controlled human trial has shown a benefit for any condition.
- How does the human body absorb and clear it after being swallowed or injected under the skin? The only trial designed to measure this (NCT02637284, registered 2015) never published results.
- Is it safe with long-term or repeated use? No human study lasted longer than two weeks and no animal cancer studies exist.
- What exactly is the parent 'BPC' protein? It was reported by one group in 1993 as a stomach-juice protein of about 40,000 daltons. I found no entry for it in the UniProt protein database (searched 18 November 2026) and did not find an independent description of the full protein. A 2025 review says BPC-157 'shows no sequence homology with known intestinal peptides'.
- How much of the animal evidence would hold up if repeated by others? Five of the six animal and overview papers cited here come from the University of Zagreb group that discovered the peptide. A 2019 review noted that 'only a handful of research groups have performed in-depth studies' and that every study it found reported positive results, which raises the possibility that negative results have gone unpublished.
- The exact date and wording of the reported late-February 2026 announcement about moving peptides back to Category 1. I found it only in news reports, not in any FDA, HHS or Federal Register document. BPC-157 was never formally placed in Category 1.
- The exact advisory committee vote on 23 July 2026. HHS states the committee voted in favour of BPC-157. The Associated Press reported the tally as 8 to 6 with one abstention. The FDA's meeting page (current as of 6 August 2026) had not posted minutes or vote results.
- Whether the HHS policy published on 30 October 2026 is now final. The Federal Register notice calls it a draft, the comment period closed in mid-November 2026, and no separate effective date is stated. I found no later notice finalising, changing or withdrawing it.
- The knee-pain record review is reported with different success figures in different places (11 of 12 in its own abstract; 7 of 12 with relief beyond six months in a later systematic review).
- Whether the 2026 hamstring trial in China (NCT07437547) is still recruiting. Its registry record has not been updated since 27 February 2026.
Sources
All 37 sources
- PubChem: BPC-157, CID 9941957 (formula, weight, CAS, synonyms). pubchem.ncbi.nlm.nih.gov
- Sikiric et al. 1993, original description of BPC and BPC 157. pubmed.ncbi.nlm.nih.gov
- Staresinic et al. 2003, rat Achilles tendon. pubmed.ncbi.nlm.nih.gov
- Krivic et al. 2006, rat Achilles tendon-to-bone (names Pliva, PLD-116, PL 14736). pubmed.ncbi.nlm.nih.gov
- Cerovecki et al. 2010, rat knee ligament. pubmed.ncbi.nlm.nih.gov
- Novinscak et al. 2008, rat muscle crush injury. pubmed.ncbi.nlm.nih.gov
- Klicek et al. 2008, rat colon fistula. pubmed.ncbi.nlm.nih.gov
- Sikiric et al. 1997, anti-inflammatory-drug gut lesions in rats. pubmed.ncbi.nlm.nih.gov
- Chang et al. 2011, rat tendon cells (Taiwan). pubmed.ncbi.nlm.nih.gov
- Hsieh et al. 2017, blood-vessel growth and VEGFR2 (Taiwan). pubmed.ncbi.nlm.nih.gov
- He et al. 2022, how rats and dogs absorb and clear BPC-157. pubmed.ncbi.nlm.nih.gov
- Xu et al. 2020, animal safety testing. pubmed.ncbi.nlm.nih.gov
- Lee and Padgett 2021, knee pain record review. pubmed.ncbi.nlm.nih.gov
- Lee et al. 2024, interstitial cystitis pilot (12 women). pubmed.ncbi.nlm.nih.gov
- Lee and Burgess 2025, intravenous pilot (2 people). pubmed.ncbi.nlm.nih.gov
- Gwyer et al. 2019, review of soft-tissue healing studies. pubmed.ncbi.nlm.nih.gov
- Vasireddi et al. 2025, systematic review in sports medicine. pmc.ncbi.nlm.nih.gov
- McGuire et al. 2025, narrative review 'Regeneration or Risk?'. pmc.ncbi.nlm.nih.gov
- Jozwiak et al. 2025, literature and patent review (raises the blood-vessel and tumour concern). pmc.ncbi.nlm.nih.gov
- Sikiric et al. 2025, reply to Jozwiak et al.. pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov NCT02637284, phase 1, 2015, no results. clinicaltrials.gov
- ClinicalTrials.gov NCT07437547, phase 2 hamstring strain, 2026, recruiting. clinicaltrials.gov
- ClinicalTrials.gov NCT07803250, phase 1 rotator cuff repair, not yet recruiting. clinicaltrials.gov
- ClinicalTrials.gov NCT07752381, peptide gummies, completed, no results. clinicaltrials.gov
- FDA briefing document on BPC-157 for the 23-24 July 2026 advisory committee, dated 11 May 2026. fda.gov
- FDA: bulk drug substances that may present significant safety risks (page current as of 22 April 2026). fda.gov
- FDA: 503A nominated substances by category, updated 14 May 2026. fda.gov
- FDA: bulk drug substances used in compounding under section 503A (page current as of 14 May 2026). fda.gov
- FDA: 23-24 July 2026 Pharmacy Compounding Advisory Committee meeting page (current as of 6 August 2026). fda.gov
- Federal Register, 16 April 2026, 91 FR 20465: advisory committee meeting notice. govinfo.gov
- Federal Register, 30 October 2026, 91 FR 68526: HHS enforcement discretion policy notice. govinfo.gov
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (the six peptides) and Appendix B (HHS reasoning); read from an Internet Archive capture of 15 November 2026. hhs.gov
- WADA 2026 Prohibited List (in force 1 January 2026). wada-ama.org
- WADA 2027 Prohibited List with tracked changes (S0 names BPC-157). wada-ama.org
- WADA 2027 Prohibited List, published 21 September 2026, in force 1 January 2027. wada-ama.org
- WADA news, 30 September 2021: WADA publishes 2022 Prohibited List (BPC-157 first included). wada-ama.org
- WADA 2027 Prohibited List: summary of major modifications and explanatory notes (S0 and peptides). wada-ama.org
Sources last checked 2026-11-18.
This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.